Frontlight ResearchEarly access
Ovarian cancer trials in United States
348 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 2Not yet taking people in United StatesIntensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer
- Where
- Pittsburgh
- Age
- 18 years and over
- People
- 28
- Run by
- Kalinski, Pawel, MD, PhD
See details and how to joinNCT07634094 - Phase 1/2Taking peopleA Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
- Where
- Fairfax, Huntersville, New York, San Antonio
- Age
- 18 years and over
- People
- 499
- Run by
- Arvinas Inc.
See details and how to joinNCT07749586 · EU 2026-525614-57-00 - No phaseTaking peopleUse of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women
- Where
- Austin, Dallas, Des Moines, Houston, Miami, Minneapolis, Morristown, Oklahoma City, Providence, Rochester, San Antonio
- Age
- 50 years to 74 years
- People
- 8,000
- Run by
- M.D. Anderson Cancer Center
See details and how to joinNCT00539162 - Phase 1Taking peoplePhase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
- Where
- Atlanta, Charlottesville, Chicago, Columbus, Detroit, Duarte, Hackensack, Indianapolis, Minneapolis, Nashville, New York, Oklahoma City, Palo Alto, Pittsburgh, San Francisco, Tampa, The Bronx
- Age
- 15 years and over
- People
- 282 worldwide
- Run by
- Xencor, Inc.
See details and how to joinNCT06276491 - Phase 1/2Taking peopleA Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Where
- Fairfax, Grand Rapids, Houston, Pittsburgh, San Antonio, St Louis
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07115043 - Phase 2Taking peopleSecondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
- Where
- Houston
- Age
- 18 years and over
- People
- 30
- Run by
- M.D. Anderson Cancer Center
See details and how to joinNCT05123807 - No phaseTaking peopleSpanish Decision Tool for Ovarian Cancer Maintenance Therapy
- Where
- Houston
- Age
- 18 years and over
- People
- 70
- Run by
- M.D. Anderson Cancer Center
See details and how to joinNCT06036810 - Phase 1Taking peopleSerial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
- Where
- Houston
- Age
- 18 years and over
- People
- 300
- Run by
- M.D. Anderson Cancer Center
See details and how to joinNCT03604315 - Phase 1Taking peopleStudy of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- Where
- Boston, Charleston, Charlotte, Cleveland, Houston, La Jolla, Los Angeles, Nashville, New York, Pittsburgh, Providence, Sacramento, Tampa
- Age
- 18 years and over
- People
- 473 worldwide
- Run by
- Bicara Therapeutics
See details and how to joinNCT04429542 - Phase 1Taking peopleIACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
- Where
- Houston
- Age
- 18 years and over
- People
- 54
- Run by
- M.D. Anderson Cancer Center
See details and how to joinNCT05039801 - Phase 1Taking peopleA Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
- Where
- Aurora, Birmingham, Boston, Buffalo, Fort Worth, Fullerton, Greenbrae, La Jolla, Lebanon, New Hyde Park, Newport Beach, New York, San Antonio, St Louis
- Age
- 18 years and over
- People
- 234 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06997029 · EU 2025-524334-26-01 - No phaseTaking peopleDeveloping New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients
- Where
- Brooklyn, Jamaica, New York, Richmond Hill
- Age
- 18 years and over
- People
- 445
- Run by
- Memorial Sloan Kettering Cancer Center
See details and how to joinNCT04751435 - Phase 1/2Taking peopleStudy of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Where
- Boston, Chicago, Houston, La Jolla, Los Angeles, New York, Portland, Richmond, San Antonio, San Francisco
- Age
- 18 years to 130 years
- People
- 695 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05417594 · EU 2023-504984-17-00 - Phase 1/2Taking peoplePhase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Where
- Aurora, Boston, Columbus, Detroit, Duarte, Fairfax, Houston, Irvine, La Jolla, Louisville, Portland, Providence
- Age
- 18 years to 130 years
- People
- 622 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05797168 · EU 2022-502576-23-00 - Phase 1Taking peopleA Study of PHST001 in Advanced Solid Tumors
- Where
- Ann Arbor, Beverly Hills, Boston, Chicago, Denver, Durham, Fairfax, Fort Worth, Grand Rapids, Houston, Irving, Lake Success, Los Angeles, Nashville, New Haven, New York, Palo Alto, San Antonio
- Age
- 18 years and over
- People
- 426
- Run by
- Pheast Therapeutics
See details and how to joinNCT06840886 - No phaseEnrolling by invitationTissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic Malignancies
- Where
- Bethesda
- Age
- 18 years and over
- People
- 500
- Run by
- National Cancer Institute (NCI)
See details and how to joinNCT03762733 - Phase 1/2Taking peopleThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Where
- Austin, Bedford, Boston, Charleston, Cleveland, Dallas, Denver, Detroit, Durham, Fairfax, Houston, Irvine, La Jolla, Los Angeles, Madison, Miami, Nashville, Newark, New Haven, New York, Oklahoma City, Orlando, Philadelphia, Pittsburgh, Port Charlotte, Portland, San Antonio, Seattle, York
- Age
- 12 years and over
- People
- 300 worldwide
- Run by
- PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750 - Phase 2Taking peopleFolate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial
- Where
- Jacksonville, Rochester, Scottsdale
- Age
- 18 years and over
- People
- 78
- Run by
- Mayo Clinic
See details and how to joinNCT06639074 - Phase 2Taking peopleRepurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer
- Where
- Atlanta
- Age
- 18 years and over
- People
- 28
- Run by
- Emory University
See details and how to joinNCT05998135 - Phase 2Taking peopleA Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
- Where
- Aurora, Austin, Cincinnati, Cleveland, Fairfax, Los Angeles, Minneapolis, Nashville, Oklahoma City, Portland, Providence, Syracuse, Teaneck
- Age
- 18 years and over
- People
- 377 worldwide
- Run by
- AbbVie
See details and how to joinNCT07024784 - Phase 1/2Taking people177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- Where
- Dothan, Grand Rapids, Houston, Omaha
- Age
- 18 years and over
- People
- 61
- Run by
- Radiopharm Theranostics, Ltd
See details and how to joinNCT07189871 - Phase 2Taking peopleEvaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients
- Where
- Rochester
- Age
- 18 years to 50 years
- People
- 98
- Run by
- Mayo Clinic
See details and how to joinNCT07460752 - Phase 2Taking peopleThe Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
- Where
- Jacksonville
- Age
- 18 years and over
- People
- 27
- Run by
- Mayo Clinic
See details and how to joinNCT07285044 - Phase 1Taking peopleA Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
- Where
- Fairfax, Maumee, Portland
- Age
- 18 years and over
- People
- 74
- Run by
- TwoStep Therapeutics, Inc.
See details and how to joinNCT07814248 - Phase 1Taking peopleA Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Where
- Boston, Charlotte, Duarte, Gilbert, Houston, Jacksonville, Los Angeles, Miami, Milwaukee, Nashville, New Brunswick, Newport Beach, New York, Pittsburgh, Portland, Round Rock, Santa Monica, Tampa, Winston-Salem
- Age
- 18 years and over
- People
- 45
- Run by
- AstraZeneca
See details and how to joinNCT05877599